Schizophrenia - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 435 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Schizophrenia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Schizophrenia - Pipeline Review, H1 2016', provides an overview of the Schizophrenia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Schizophrenia
- The report reviews pipeline therapeutics for Schizophrenia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Schizophrenia therapeutics and enlists all their major and minor projects
- The report assesses Schizophrenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Schizophrenia


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Schizophrenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
Introduction 6
Schizophrenia Overview 7
Therapeutics Development 8
Schizophrenia - Therapeutics under Development by Companies 10
Schizophrenia - Therapeutics under Investigation by Universities/Institutes 17
Schizophrenia - Pipeline Products Glance 18
Schizophrenia - Products under Development by Companies 22
Schizophrenia - Products under Investigation by Universities/Institutes 32
Schizophrenia - Companies Involved in Therapeutics Development 33
Schizophrenia - Therapeutics Assessment 112
Drug Profiles 129
Schizophrenia - Recent Pipeline Updates 329
Schizophrenia - Dormant Projects 387
Schizophrenia - Discontinued Products 402
Schizophrenia - Product Development Milestones 408
Appendix 416

List of Tables

Number of Products under Development for Schizophrenia, H1 2016 26
Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2016 27
Number of Products under Development by Companies, H1 2016 29
Number of Products under Development by Companies, H1 2016 (Contd..1) 30
Number of Products under Development by Companies, H1 2016 (Contd..2) 31
Number of Products under Development by Companies, H1 2016 (Contd..3) 32
Number of Products under Development by Companies, H1 2016 (Contd..4) 33
Number of Products under Development by Companies, H1 2016 (Contd..5) 34
Number of Products under Investigation by Universities/Institutes, H1 2016 35
Comparative Analysis by Late Stage Development, H1 2016 36
Comparative Analysis by Clinical Stage Development, H1 2016 37
Comparative Analysis by Early Stage Development, H1 2016 38
Comparative Analysis by Unknown Stage Development, H1 2016 39
Products under Development by Companies, H1 2016 40
Products under Development by Companies, H1 2016 (Contd..1) 41
Products under Development by Companies, H1 2016 (Contd..2) 42
Products under Development by Companies, H1 2016 (Contd..3) 43
Products under Development by Companies, H1 2016 (Contd..4) 44
Products under Development by Companies, H1 2016 (Contd..5) 45
Products under Development by Companies, H1 2016 (Contd..6) 46
Products under Development by Companies, H1 2016 (Contd..7) 47
Products under Development by Companies, H1 2016 (Contd..8) 48
Products under Development by Companies, H1 2016 (Contd..9) 49
Products under Investigation by Universities/Institutes, H1 2016 50
Schizophrenia - Pipeline by AbbVie Inc., H1 2016 51
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc., H1 2016 52
Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc., H1 2016 53
Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H1 2016 54
Schizophrenia - Pipeline by AgeneBio Inc., H1 2016 55
Schizophrenia - Pipeline by Alkermes Plc, H1 2016 56
Schizophrenia - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 57
Schizophrenia - Pipeline by Amgen Inc., H1 2016 58
Schizophrenia - Pipeline by Angita B.V., H1 2016 59
Schizophrenia - Pipeline by Astellas Pharma Inc., H1 2016 60
Schizophrenia - Pipeline by AstraZeneca Plc, H1 2016 61
Schizophrenia - Pipeline by Athersys, Inc., H1 2016 62
Schizophrenia - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016 63
Schizophrenia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 64
Schizophrenia - Pipeline by BioCrea GmbH, H1 2016 65
Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H1 2016 66
Schizophrenia - Pipeline by Braeburn Pharmaceuticals, Inc., H1 2016 67
Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H1 2016 68
Schizophrenia - Pipeline by Coronis Partners Ltd., H1 2016 69
Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H1 2016 70
Schizophrenia - Pipeline by Curemark, LLC, H1 2016 71
Schizophrenia - Pipeline by Delpor, Inc., H1 2016 72
Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H1 2016 73
Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H1 2016 74
Schizophrenia - Pipeline by Eli Lilly and Company, H1 2016 75
Schizophrenia - Pipeline by Evotec AG, H1 2016 76
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 77
Schizophrenia - Pipeline by FORUM Pharmaceuticals Inc., H1 2016 78
Schizophrenia - Pipeline by Galenea Corp., H1 2016 79
Schizophrenia - Pipeline by GeNeuro SA, H1 2016 80
Schizophrenia - Pipeline by Gilead Sciences, Inc., H1 2016 81
Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 82
Schizophrenia - Pipeline by GP Pharm, S.A., H1 2016 83
Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H1 2016 84
Schizophrenia - Pipeline by H. Lundbeck A/S, H1 2016 85
Schizophrenia - Pipeline by Heptares Therapeutics Limited, H1 2016 86
Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 87
Schizophrenia - Pipeline by Indivior Plc, H1 2016 88
Schizophrenia - Pipeline by INSYS Therapeutics, Inc., H1 2016 89
Schizophrenia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016 90
Schizophrenia - Pipeline by IntelGenx Corp., H1 2016 91
Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 92
Schizophrenia - Pipeline by Iproteos S.L., H1 2016 93
Schizophrenia - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H1 2016 94
Schizophrenia - Pipeline by Johnson & Johnson, H1 2016 95
Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H1 2016 96
Schizophrenia - Pipeline by KemPharm, Inc., H1 2016 97
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2016 98
Schizophrenia - Pipeline by Lead Discovery Center GmbH, H1 2016 99
Schizophrenia - Pipeline by Lohocla Research Corporation, H1 2016 100
Schizophrenia - Pipeline by Luc Therapeutics, Inc., H1 2016 101
Schizophrenia - Pipeline by Luye Pharma Group Ltd., H1 2016 102
Schizophrenia - Pipeline by Mapi Pharma Ltd., H1 2016 103
Schizophrenia - Pipeline by Merck & Co., Inc., H1 2016 104
Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 105
Schizophrenia - Pipeline by Neuralstem, Inc., H1 2016 106
Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H1 2016 107
Schizophrenia - Pipeline by NeurOp, Inc, H1 2016 108
Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H1 2016 109
Schizophrenia - Pipeline by Omeros Corporation, H1 2016 110
Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 111
Schizophrenia - Pipeline by Peptron, Inc., H1 2016 112
Schizophrenia - Pipeline by Pfizer Inc., H1 2016 113
Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H1 2016 114
Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 115
Schizophrenia - Pipeline by Richter Gedeon Nyrt., H1 2016 116
Schizophrenia - Pipeline by Saniona AB, H1 2016 117
Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 118
Schizophrenia - Pipeline by Spherium Biomed S.L., H1 2016 119
Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 120
Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 121
Schizophrenia - Pipeline by Suven Life Sciences Ltd., H1 2016 122
Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 123
Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 124
Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H1 2016 125
Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 126
Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H1 2016 127
Schizophrenia - Pipeline by Zogenix, Inc., H1 2016 128
Schizophrenia - Pipeline by Zysis Limited, H1 2016 129
Assessment by Monotherapy Products, H1 2016 130
Assessment by Combination Products, H1 2016 131
Number of Products by Stage and Target, H1 2016 133
Number of Products by Stage and Mechanism of Action, H1 2016 139
Number of Products by Stage and Route of Administration, H1 2016 144
Number of Products by Stage and Molecule Type, H1 2016 146
Schizophrenia Therapeutics - Recent Pipeline Updates, H1 2016 347
Schizophrenia - Dormant Projects, H1 2016 405
Schizophrenia - Dormant Projects (Contd..1), H1 2016 406
Schizophrenia - Dormant Projects (Contd..2), H1 2016 407
Schizophrenia - Dormant Projects (Contd..3), H1 2016 408
Schizophrenia - Dormant Projects (Contd..4), H1 2016 409
Schizophrenia - Dormant Projects (Contd..5), H1 2016 410
Schizophrenia - Dormant Projects (Contd..6), H1 2016 411
Schizophrenia - Dormant Projects (Contd..7), H1 2016 412
Schizophrenia - Dormant Projects (Contd..8), H1 2016 413
Schizophrenia - Dormant Projects (Contd..9), H1 2016 414
Schizophrenia - Dormant Projects (Contd..10), H1 2016 415
Schizophrenia - Dormant Projects (Contd..11), H1 2016 416
Schizophrenia - Dormant Projects (Contd..12), H1 2016 417
Schizophrenia - Dormant Projects (Contd..13), H1 2016 418
Schizophrenia - Dormant Projects (Contd..14), H1 2016 419
Schizophrenia - Discontinued Products, H1 2016 420
Schizophrenia - Discontinued Products (Contd..1), H1 2016 421
Schizophrenia - Discontinued Products (Contd..2), H1 2016 422
Schizophrenia - Discontinued Products (Contd..3), H1 2016 423
Schizophrenia - Discontinued Products (Contd..4), H1 2016 424
Schizophrenia - Discontinued Products (Contd..5), H1 2016 425